Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
紫色生物技术公布了在ASCO 2024上报告的一项2期研究结果，显示CM24可以改善胰腺癌的总生存率和其他疗效终点。
- 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim data
- Prolongation of 2.1 months in median overall survival (OS) and 1.9 months in median progression-free survival (PFS) in the CM24+nivolumab+Nal-IRI/5FU/LV regimen vs. standard-of-care
- Data supported by higher objective response rate (ORR) (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase)
- 根据初步的中期数据，先前接受过治疗的患者使用CM24 + nivolumab + Nal / IRI / 5FU / LV相比标准惯例治疗，死亡风险降低了26％（HR = 0.74），疾病进展或死亡的风险降低了28％（HR = 0.72）。
- 使用 CM24 + nivolumab + Nal-IRI / 5FU / LV 方案相比标准惯例治疗，中位总生存期（OS）延长了2.1个月，中位无进展生存期（PFS）延长了1.9个月。
- 数据支持使用 CM24 + nivolumab + Nal / IRI / 5FU / LV 方案较之标准惯例治疗可获得更高的客观缓解率（ORR）（25％ vs 7％），疾病控制率（DCR）（63％ vs 40％）以及血清CA19-9水平下降（61％下降 vs 34％上升）。